Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.71 |
| ▸ | IL2 | P60568 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | PRKCA | P17252 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 5/20 | 0.39 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL124603 | 0.96 | BACE1 (0.77) | BACE1IL2POLBKDM4EGAA | |
| SCHEMBL7631773 | 0.96 | BACE1 (0.77) | BACE1IL2POLBKDM4EGAA | |
| SCHEMBL124604 | 0.96 | BACE1 (0.77) | BACE1IL2POLBKDM4EGAA | |
| SCHEMBL22400844 | 0.87 | BACE1 (0.64) | BACE1IL2POLBKDM4EGAA | |
| Allicin SCHEMBL5451006 | 0.86 | BACE1 (0.63) | BACE1IL2POLBKDM4EGAA | |
| Honokiol SCHEMBL3837036 | 0.86 | BACE1 (0.62) | BACE1IL2POLBKDM4EGAA | |
| Oleuropein SCHEMBL23559534 | 0.83 | BACE1 (1.00) | BACE1IL2POLBKDM4EGAA | |
| Oleuropein SCHEMBL24452037 | 0.83 | BACE1 (1.00) | BACE1IL2POLBKDM4EGAA | |
| Oleuropein SCHEMBL21481089 | 0.83 | BACE1 (1.00) | BACE1IL2POLBKDM4EGAA | |
| Oleuropein SCHEMBL23133255 | 0.83 | BACE1 (1.00) | BACE1IL2POLBKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125869-A1 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS | Omphax SA (GR) | 2022-04-28 | — | — | US | disclosed |
| US-20220125869-A1 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS | Omphax SA (GR) | 2022-04-28 | — | — | US | disclosed |
| EP-3924081-A2 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS | Omphax SA (GR) | 2021-12-22 | — | — | EP | disclosed |
| EP-3924081-A2 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS | Omphax SA (GR) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020165614-A9 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS | MAGIATIS PROKOPIOS (GR) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020165614-A3 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS | MAGIATIS PROKOPIOS (GR) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020165614-A2 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS | MAGIATIS PROKOPIOS (GR) | 2020-08-20 | — | — | WO | disclosed |
| WO-2020165614-A2 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS | MAGIATIS PROKOPIOS (GR) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125869-A1 | METHOD FOR OBTAINING OLEOCANTHAL TYPE SECOIRIDOIDS AND FOR PRODUCING RESPECTIVE PHARMACEUTICAL PREPARATIONS | CYP46A1, LIPA, SQLE | BACE1 252/4885IL2 1322/4885POLB 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.